Gamida Cell Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gamida Cell in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Gamida Cell stock.
View analyst ratings for Gamida Cell or view top-rated stocks.

Wall Street analysts have given Gamida Cell a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Gamida Cell wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Gamida Cell saw a increase in short interest during the month of February. As of February 12th, there was short interest totaling 1,330,000 shares, an increase of 83.5% from the January 28th total of 724,800 shares. Based on an average trading volume of 1,200,000 shares, the short-interest ratio is presently 1.1 days.
View Gamida Cell's Short Interest.

Gamida Cell is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021.
View our earnings forecast for Gamida Cell.

Gamida Cell will be holding an earnings conference call on Tuesday, March 9th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Gamida Cell Ltd. (NASDAQ:GMDA) issued its quarterly earnings results on Sunday, November, 15th. The company reported ($0.30) EPS for the quarter, topping the Zacks' consensus estimate of ($0.31) by $0.01.
View Gamida Cell's earnings history.

Gamida Cell's stock was trading at $4.23 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, GMDA stock has increased by 92.7% and is now trading at $8.15.
View which stocks have been most impacted by COVID-19.

5 Wall Street analysts have issued 1-year price objectives for Gamida Cell's stock. Their forecasts range from $13.00 to $27.00. On average, they expect Gamida Cell's share price to reach $18.50 in the next twelve months. This suggests a possible upside of 127.0% from the stock's current price.
View analysts' price targets for Gamida Cell or view top-rated stocks among Wall Street analysts.

Some companies that are related to Gamida Cell include Cellectis (CLLS), Adaptimmune Therapeutics (ADAP), Orchard Therapeutics (ORTX), CEL-SCI (CVM), Vaxart (VXRT), Osiris Therapeutics (OSIR), Tarsus Pharmaceuticals (TARS), Athira Pharma (ATHA), Agenus (AGEN), DBV Technologies (DBVT), Solid Biosciences (SLDB), Precision BioSciences (DTIL), MeiraGTx (MGTX), Poseida Therapeutics (PSTX) and Jounce Therapeutics (JNCE).
View all of GMDA's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Gamida Cell investors own include Matinas BioPharma (MTNB), Bionano Genomics (BNGO), Gran Tierra Energy (GTE), ADMA Biologics (ADMA), Pennsylvania Real Estate Investment Trust (PEI), Zosano Pharma (ZSAN), Cannabics Pharmaceuticals (CNBX), KushCo (KSHB), Enerplus (ERF) and Novan (NOVN).

(GMDA) raised $50 million in an initial public offering (IPO) on Friday, October 26th 2018. The company issued 3,600,000 shares at $13.00-$15.00 per share. BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and Needham & Company Oppenheimer & Co. was co-manager.

Gamida Cell trades on the NASDAQ under the ticker symbol "GMDA."

Gamida Cell's stock is owned by a number of institutional and retail investors. Top institutional investors include Federated Hermes Inc. (20.86%), Baker BROS. Advisors LP (6.39%), BlackRock Inc. (1.81%), Stonepine Capital Management LLC (1.57%), Ikarian Capital LLC (0.66%) and Victory Capital Management Inc. (0.53%).

GMDA stock was sold by a variety of institutional investors in the last quarter, including Meitav Dash Investments Ltd., Phoenix Holdings Ltd., Squarepoint Ops LLC, and Victory Capital Management Inc..

GMDA stock was acquired by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Baker BROS. Advisors LP, BlackRock Inc., Stonepine Capital Management LLC, Ikarian Capital LLC, Silverarc Capital Management LLC, Virtus ETF Advisers LLC, and Barclays PLC.

Shares of GMDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GMDA stock can currently be purchased for approximately $8.15.

Gamida Cell has a market capitalization of $197.39 million. The company earns $-34,350,000.00 in net income (profit) each year or ($1.69) on an earnings per share basis.

Gamida Cell employs 79 workers across the globe.

The official website for Gamida Cell is www.gamida-cell.com.

Gamida Cell is headquartered at 5 NAHUM HAFZADI STREET GIVAAT SHAUL, JERUSALEM L3, 91340.

Gamida Cell's mailing address is 5 NAHUM HAFZADI STREET GIVAAT SHAUL, JERUSALEM L3, 91340. The company can be reached via phone at 972-2659-5666 or via email at [email protected]